Literature DB >> 9772291

Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells.

Q Li1, L Ding, J J Yu, C Mu, B Tsang, F Bostick-Bruton, E Reed.   

Abstract

Nucleotide excision repair (NER) is the DNA repair pathway by which cisplatin-induced damage is removed from DNA in human cells. ERCC-1 is one of the essential proteins in NER, and is essential for life. Enhanced ERCC-1 expression has been associated with clinical and cellular resistance to cisplatin. We therefore carried out this study to investigate the effect of cisplatin on ERCC-1 protein expression in A2780/CP70 human ovarian cancer cells. Western blot analysis showed that ERCC-1 protein levels were increased to more than 3 times control after a 1 h cisplatin exposure to A2780/CP70 cells in culture. This increase was time- and concentration-dependent. The effect of cisplatin was maximal at 40 mM and peaked 24-48 h after exposure to the drug. These results extend our previous observations that ERCC-1 mRNA expression is induced by cisplatin in this system. TPA, a known AP-1 activator and tumor-promoting phorbol ester, also induced ERCC-1 protein to the same extent as cisplatin, but did not synergize with cisplatin in this regard. These findings suggest that ERCC-1 gene up-regulation in these cells can result through a DNA damage-response pathway, or through the induction of AP-1 activity, independent of the occurrence of DNA damage.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9772291     DOI: 10.3892/ijo.13.5.987

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

1.  Mesothelioma: a review.

Authors:  Frank E Mott
Journal:  Ochsner J       Date:  2012

Review 2.  Causes of genome instability: the effect of low dose chemical exposures in modern society.

Authors:  Sabine A S Langie; Gudrun Koppen; Daniel Desaulniers; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Amaya Azqueta; William H Bisson; Dustin G Brown; Gunnar Brunborg; Amelia K Charles; Tao Chen; Annamaria Colacci; Firouz Darroudi; Stefano Forte; Laetitia Gonzalez; Roslida A Hamid; Lisbeth E Knudsen; Luc Leyns; Adela Lopez de Cerain Salsamendi; Lorenzo Memeo; Chiara Mondello; Carmel Mothersill; Ann-Karin Olsen; Sofia Pavanello; Jayadev Raju; Emilio Rojas; Rabindra Roy; Elizabeth P Ryan; Patricia Ostrosky-Wegman; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Frederik J Van Schooten; Mahara Valverde; Jordan Woodrick; Luoping Zhang; Nik van Larebeke; Micheline Kirsch-Volders; Andrew R Collins
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

3.  XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.

Authors:  Alec Vaezi; Xiaozhe Wang; Shama Buch; William Gooding; Lin Wang; Raja R Seethala; David T Weaver; Alan D D'Andrea; Athanassios Argiris; Marjorie Romkes; Laura J Niedernhofer; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

4.  Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.

Authors:  Jennifer M Rubatt; Kathleen M Darcy; Chunqiao Tian; Franco Muggia; Rajiv Dhir; Deborah K Armstrong; Michael A Bookman; Laura J Niedernhofer; Julie Deloia; Michael Birrer; Thomas Carl Krivak
Journal:  Gynecol Oncol       Date:  2012-01-16       Impact factor: 5.482

5.  β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK.

Authors:  Quentin Q Li; Rebecca X Lee; Huasheng Liang; Gangduo Wang; Jueli M Li; Yuhua Zhong; Eddie Reed
Journal:  Int J Oncol       Date:  2013-06-28       Impact factor: 5.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.